Clinical Trials Logo

Angina Pectoris, Variant clinical trials

View clinical trials related to Angina Pectoris, Variant.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06176391 Not yet recruiting - Clinical trials for Angina Pectoris; Angiospastic

SCS for Vasospastic Angina Vasospastic Angina Pectoris - a Prospective Study

VAP
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

According to the 2020 Dutch guideline on chest pain (AP) without obstructive coronary artery disease, 70% of female and 30% of male patients undergoing a coronary angiogram (CAG), have no obstructive coronary artery disease.In the majority of patients the complaints are based on vascular dysfunction, including epicardial vascular spasms. For patients who are refractory to drug treatment, spinal cord stimulation (SCS) can be a treatment option. SCS is used for the treatment of refractory neuropathic and ischaemic pain. In recent studies the use of SCS is proven for refractory angina pectoris, but the group with refractory vasospastic angina pectoris (rVSA) predominantly seen in women with invalidating impairment of quality of life, is overlooked, as no evidence of obstruction is found at CAG. With this pilot study the investigators hypothesize that SCS is effective in reducing the number and intensity of angina attacks, reducing nitrate use, reducing inhospital treatment and ER presentations, thereby reducing medical costs, and above all, increasing quality of life.

NCT ID: NCT03054467 Not yet recruiting - Quality of Life Clinical Trials

Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina

SCARLET
Start date: December 1, 2018
Phase: Phase 4
Study type: Interventional

The aim of the present study is to compare the effects of CCB and CCB+ high dose of statin therapy on the symptoms, function, and quality of life assessed by validated angina-specific questionnaire (Short-form Seattle Angina Questionnaire (SAQ-7)), endothelial function as measured by FMD of the brachial artery, endothelial progenitor cells (EPC) and coronary flow reserve (CFR) in patients with VSA.